Open AccessMechanisms of action and adverse effects of the major therapeutic agents in trial for COVID-19 therapeutics: Review of literature
Author(s) -
Emeka Ogiji,
Obumneme Ezeanosike,
Casimir C. Ofor,
Edak Ezeanosike,
Charles Chidiebele Maduba,
Samuel Ghasi
Publication year - 2021
Publication title -
annals of clinical and biomedical research
Language(s) - English
Resource type - Journals
ISSN - 2724-508X
DOI - 10.4081/acbr.2021.118
Subject(s) - medicine , adverse effect , clinical trial , intensive care medicine , hydroxychloroquine , tocilizumab , pharmacology , covid-19 , rheumatoid arthritis , disease , infectious disease (medical specialty)
The race to find an effective cure for COVID-19 is on. Most of the candidate drugs in various clinical trials are being re-purposed but none has been approved as at date. It is pertinent for the bedside physicians to understand the mechanisms of action of these agents and their peculiar adverse effects so they are properly guided on the risk/benefit of the drugs they choose in managing COVID-19 patients. Clinicaltrials.gov, the international clinical trials platform of the WHO, the EU clinical trials register and the Cochrane Central Register of Controlled Trials were searched for registered clinical trials. Studies in therapeutic trials were considered eligible for the work. Frequency table was made for the most common trialled drugs and the mechanisms of actions and adverse effects of the selected drugs were reviewed. Ten studies were selected for review in a descending order of their frequency in different therapeutic trials and these are ritonavir, lopinavir, chloroquine/ hydroxychloroquine, interferon, remdesvir, favipravir, umifenovir, darunavir, tocilizumab and methylprednisolone. The bedside physicians need to understand the mechanisms of action of these agents and their peculiar adverse effects for proper guidance on the risk/benefit of the drugs they choose in managing COVID- 19 patients.